

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hansoh Pharmaceutical Group Company Limited

翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

VOLUNTARY ANNOUNCEMENT

DRUG REGISTRATION APPROVAL OF THE THIRD INDICATION OF XINYUE (INEBILIZUMAB INJECTION) WAS GRANTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

The board of directors (the “**Board**”) of Hansoh Pharmaceutical Group Company Limited (the “**Company**”) and together with its subsidiaries, the “**Group**”) is pleased to announce that, on March 25, 2026, the innovative drug XINYUE (昕越®) (Inebilizumab Injection) (the “**Product**”) has been granted drug registration approval by the National Medical Products Administration of China (the “**NMPA**”), approving the addition of an indication: the product is used in combination with conventional therapeutic drugs for the treatment of adult patients with generalized myasthenia gravis (gMG) who are positive for anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies. This is the third indication of XINYUE which has been approved.

ABOUT THE PRODUCT

Inebilizumab is a targeted CD19 B-cell depleting antibody. In May 2019, the Group entered into a license agreement with Viela Bio (Viela Bio was acquired by Horizon Therapeutics in 2021, which was acquired by Amgen in 2023), and has been granted an exclusive license to develop and commercialize the Product in Chinese Mainland, Hong Kong and Macau. In March 2022, the Product was approved to be launched in China by the NMPA for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. In January 2023, the Product was included in the National Reimbursement Drug List (NRDL) for the first time, and this inclusion was successfully renewed in November 2024. In August 2025, the second indication of the Product has been approved in China for immunoglobulin G4-related disease (IgG4-RD) in adult patients.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, March 27, 2026

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Ms. Sun Yuan and Dr. Lyu Aifeng as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai, Ms. Yang Dongtao and Mr. Yan Jia as independent non-executive directors.